Review of Rational Approaches to the Treatment of Pain Management-Role for Opioids Therapies

被引:0
作者
Modi, Pankaj [1 ]
机构
[1] Innovatech Rx, 519 Golf Links Rd, Ancaster, ON L9G 4X6, Canada
关键词
Chronic pain; breakthrough pain; degenerative joint diseases; fibromyalgia; visceral diseases; cancer; opioids; hydromorphone; hydrocodone; oxycodone; tramadol; fentanyl; meperidine; methadone; propoxyphene; and levorphanol;
D O I
10.2174/157488508783331199
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Opioids remain an important cornerstone and the most effective mainstay analgesics for acute and terminal cancer pain treatments. Effective analgesia is obtained in the majority of cancer pain patients with the application of fairly straightforward rational treatment algorithms using opioids as the main therapy. A major barrier to be overcome, however, is that chronic pain is often not viewed as a physical illness worthy of treatment. Many studies demonstrating that specific changes occur in the peripheral and central nervous systems of patients with chronic pain provide the rationale for changing the approaches to chronic pain management and instituting more aggressive and comprehensive treatment. This review describes the role of opioids in the treatment of cancer pain, including a brief overview of cancer pain syndromes, essential aspects of opioid therapy, opioid pharmacology, opioid rotation, properties of the individual opioids, and management of common side effects of opioids. As understanding of the pharmacology of this class of drugs becomes more sophisticated, clinicians may anticipate dosage-limiting adverse effects and variations in individual response.
引用
收藏
页码:33 / 43
页数:11
相关论文
共 87 条
[21]   Effects of prolonged exposure to morphine and methadone on in vivo parameters of immune function in rats [J].
De Waal, EJ ;
Van Der Laan, JW ;
Van Loveren, H .
TOXICOLOGY, 1998, 129 (2-3) :201-210
[22]   Opioids in renal failure and dialysis patients [J].
Dean, M .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2004, 28 (05) :497-504
[23]  
Duragesic, 2005, JANSS PHARM PROD L P
[24]   Serotonin syndrome attributed to tramadol addition to paroxetine therapy [J].
Egberts, ACG ;
terBorgh, J ;
BrodieMeijer, CCE .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1997, 12 (03) :181-182
[25]   THE NMDA RECEPTOR ANTAGONISTS, LY274614 AND MK-801, AND THE NITRIC-OXIDE SYNTHASE INHIBITOR, NG-NITRO-L-ARGININE, ATTENUATE ANALGESIC TOLERANCE TO THE MU-OPIOID MORPHINE BUT NOT TO KAPPA-OPIOIDS [J].
ELLIOTT, K ;
MINAMI, N ;
KOLESNIKOV, YA ;
PASTERNAK, GW ;
INTURRISI, CE .
PAIN, 1994, 56 (01) :69-75
[26]   Critical issues on opioids in chronic non-cancer pain: An epidemiological study [J].
Eriksen, Jorgen ;
Sjogren, Per ;
Bruera, Eduardo ;
Ekholm, Ola ;
Rasmussen, Niels K. .
PAIN, 2006, 125 (1-2) :172-179
[27]   Hypogonadism in patients treated with intrathecal morphine [J].
Finch, PM ;
Roberts, LJ ;
Price, L ;
Hadlow, NC ;
Pullan, PT .
CLINICAL JOURNAL OF PAIN, 2000, 16 (03) :251-254
[28]   Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal [J].
Finn, AK ;
Whistler, JL .
NEURON, 2001, 32 (05) :829-839
[29]   Methadone reincarnated: Novel clinical applications with related concerns [J].
Fishman, SM ;
Wilsey, B ;
Mahajan, G ;
Molina, P .
PAIN MEDICINE, 2002, 3 (04) :339-348
[30]  
FISHMAN SM, 2002, MASSACHUSETTS GEN HO